Our work on benchmarking efficiency is now out: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0653-z
It uses some very cool econ and OR methods, and it even has a press release: http://www.healthdata.org/news-release/improving-health-facility-efficiency-could-markedly-expand-hiv-treatment :
“Improving efficiency can support major gains in expanding ART to people who need treatment, especially when funding is limited,” says IHME Assistant Professor Abraham Flaxman, senior author of the study. “Now we, as a global health community, need to figure out how.”
A question that has been coming up in a lot of different forms lately is the title of this post: What are HIV+ patients dying of? In high-income settings, for people who are getting treatment, the answer seems to be known, by those in the know, and perhaps the definitive work is Causes of Death in HIV-1–Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort Studies.
Left unanswered is what is going on with people who are not getting treatment, who are not diagnosed, and who are not living in Europe or North America.